Report Highlights
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period. Clinical trial spending in 2010 is an estimated $25 billion and is expected to reach $28.5 billion by 2014.
SCOPE OF REPORT
The report provides an overview of clinical development phases, the regulatory issues involved, and the factors influencing clinical trial costs. An overview is provided of new technologies that will be affecting the clinical trial process in the near future. Major product pipelines are provided by physiological system and company.
ANALYST CREDENTIALS
Jon Evans has been involved in business development and research for the medical industry since 1984. Mr. Evans’ career includes 4 years as a diagnostic systems sales representative and over 15 years in market research and strategy analysis with Fortune 500 clients. He has developed expertise in assessing the unique business development challenges facing firms in the medical industry and designing strategies to optimize market performance. Mr. Evans received a BS in biology from Rutgers University in 1983, and an MBA in business analysis from San Francisco State University in 1989.
Related Reports
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Global Vaccine Adjuvants Market
This report provides an analysis of the global market for vaccine adjuvants. It focuses on the key driving trends and challenges. The study evaluates the competitive landscape, reviews key technological developments, and provides market estimates and forecasts through 2031.
Global Topical Drug Delivery Market
The global topical drug delivery market was valued at $222.9 billion in 2025 and is estimated to increase from $239 billion in 2026 to reach $362.3 billion by the end of 2031, at a compound annual growth rate (CAGR) of 8.7% from 2026 to 2031.
Blood Cancer Therapeutics: Global Markets to 2030
The global market for blood cancer therapeutics was valued at $77.1 billion in 2025 and is projected to reach $125.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2030.
Clinical Nutrition: Global Markets to 2031
The global market for clinical nutrition is expected to grow from $79.5 billion in 2026 and is projected to reach $104.7 billion by the end of 2031, at a compound annual growth rate (CAGR) of 5.6% during the forecast period of 2026 to 2031.
Substance Use Disorder Treatment: Global Markets to 2030
The global substance use disorder (SUD) treatment market was valued at $11.6 billion in 2025, and it is expected to reach $14.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2030.
Top Trending Reports
Global Enterprise Artificial Intelligence (AI) Market
This study examines the global enterprise AI market across key segments such as component, software deployment, technology, organization size, end user and geography. It focuses on commercially deployed AI software, services and hardware generating revenue across industries, including new deployments and the expansion of existing AI infrastructure. The analysis also covers emerging technologies, major market trends and challenges, the competitive landscape and profiles of leading companies. Regional market trends are assessed using 2025 as the base year, with forecasts from 2026 through 2031.
Outpatient Surgical Procedures: Global Markets
The global market for outpatient surgical procedures is expected to grow from $381.9 billion in 2026 and is projected to reach $598.6 billion by the end of 2031, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2026 to 2031.
Global Markets for Fermentation Ingredients
The global market for fermentation ingredients is expected to grow from $39.8 billion in 2026 and is projected to reach $53.4 billion by the end of 2031, at a compound annual growth rate (CAGR) of 6.1% during the forecast period of 2026 to 2031.
Global Pathology Services Market
The global market for pathology services was valued at $225 billion in 2025 and, is estimated to reach $307.9 billion by 2030, at a compound annual growth rate (CAGR) of 6.5% from 2025 through 2030.
The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
The U.S. market for biodefense-related rapid pathogen identification and treatments is expected to grow from $8.4 billion in 2026 and is projected to reach $12.1 billion by the end of 2031, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2026 to 2031.
Report Highlights
-
National spending on clinical trials was nearly $24 billion in 2005. By 2006 this number will rise to $25.6 billion and then $32.1 billion in 2011, an average annual growth rate (AAGR) of 4.6%. In 2005, biotechnology and pharmaceutical companies spent approximately $51 billion on research and development efforts, with $21 billion (41%) spent on clinical trials. In comparison, government contributions to clinical trials were considerably smaller. The National Institutes of Health spent $2.9 billion on clinical trials in 2005 and budgeted $3.0 billion for 2006.
-
Total funding for 2005 was $24.4 billion. In 2006 this number will rise to $26 billion and in 2011 to $32.6 billion, an AAGR of 4.6%
-
The number of clinical trials performed in 2005 was 8,386. BCC Research predicts this number will reach almost 10,000 by 2006. At an AAGR of 5.8%, the number of clinical trials performed in 2011 will reach more than 13,000.
Report Highlights
-
The number of clinical trials in the US reached 2,519 in 2002.
-
They will increase at an average annual growth rate (AAGR) of 12.3%.
-
By 2007, $26.555 billion will be spent on clinical trials.
-
R&D budgets will increase at an AAGR of at least 10%.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More